Blair William & CO Inhibikase Therapeutics, Inc. Transaction History

Blair William & CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.54 - $0.91 $25,380 - $42,770	47,000 Added 20.52%	276,000 $182,000
Q4 2022 Feb 10, 2023	BUY	$0.45 - $0.78 $22,500 - $39,000	50,000 Added 27.93%	229,000 $114,000
Q3 2022 Nov 09, 2022	BUY	$0.76 - $1.11 $117,040 - $170,940	154,000 Added 616.0%	179,000 $163,000
Q2 2022 Aug 10, 2022	BUY	$0.63 - $1.44 $15,750 - $36,000	25,000 New	25,000 $19,000

1.03M

Ticker IKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,227,100
Market Cap $29.3M
Description
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

Stay updated on Blair William & CO with notifications on news.